{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer&page=28", "query": { "condition": "Gastric Cancer", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 1089, "total_pages": 109, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Cancer&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T03:10:15.685Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03890731", "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Cancer" ], "interventions": [ { "name": "BAY73-4506 (Regorafenib, Stivarga)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2019-04-02", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03890731" }, { "nct_id": "NCT04682431", "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Gynecologic Cancer", "Breast Cancer", "Colorectal Cancer", "Gastric Adenocarcinoma", "Lung Adenocarcinoma", "Pancreatic Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "PY159 Single agent dose level 1", "type": "DRUG" }, { "name": "PY159 Single agent dose level 2", "type": "DRUG" }, { "name": "PY159 Single agent dose level 3", "type": "DRUG" }, { "name": "PY159 Single agent dose level 4", "type": "DRUG" }, { "name": "PY159 Single agent dose level 5", "type": "DRUG" }, { "name": "PY159 Single agent dose level 6", "type": "DRUG" }, { "name": "PY159 Single agent dose level 7", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 1", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 2", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 3", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose level 4", "type": "DRUG" }, { "name": "PY159 Single agent dose expansion cohort", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 1", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 2", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 3", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 4", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 5", "type": "DRUG" }, { "name": "PY159/Pembrolizumab Combination dose expansion cohort 6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ikena Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2020-11-10", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 17, "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04682431" }, { "nct_id": "NCT00517829", "title": "Docetaxel+Oxali+/-Cetux Met Gastric/GEJ", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer Adenocarcinoma Metastatic" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2007-07", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2016-11-28", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Denver, Colorado + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517829" }, { "nct_id": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head & Neck Squamous Cell Carcinoma", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Colorectal Cancer", "Endometrial Cancer", "Urothelial Carcinoma (UC)", "Breast Cancer" ], "interventions": [ { "name": "STRO-006", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2026-10-19", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 6, "location_summary": "Orlando, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 3 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Irving", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807345" }, { "nct_id": "NCT04670445", "title": "Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IV Melanoma", "Advanced Lung Cancer", "Stage IV Non-Small Cell Lung Cancer", "Unresectable Non-Small Cell Lung Carcinoma", "Unresectable Stage III Non-Small Cell Lung Cancer", "Small Cell Lung Cancer Extensive Stage", "Stage IV Merkel Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma", "Stage IV Basal Cell Carcinoma", "Stage IV Breast Cancer", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Hepatocellular Cancer", "Stage IV Renal Cell Carcinoma", "Stage IV Bladder Cancer", "Stage IV Head and Neck Squamous Cell Carcinoma", "Stage IV Cervical Cancer", "Stage IV Endometrial Cancer", "Stage IV Mesothelioma", "Immunotherapy", "Immune Checkpoint Inhibitors" ], "interventions": [ { "name": "Educational Video and QPL List", "type": "OTHER" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2021-01-23", "completion_date": "2024-04-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670445" }, { "nct_id": "NCT05002127", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2022-01-15", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 5, "location_summary": "Anaheim, California • Los Angeles, California • Nashville, Tennessee + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002127" }, { "nct_id": "NCT03576872", "title": "The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastro Intestinal Cancer" ], "interventions": [ { "name": "Psychoeducational", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-07-09", "completion_date": "2019-09-30", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03576872" }, { "nct_id": "NCT03597581", "title": "A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Cancer", "Gastrointestinal Neoplasms", "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Gastric Cancer", "Gastric Neoplasm", "KRAS Mutation-Related Tumors", "CRC", "Colorectal Cancer Metastatic" ], "interventions": [ { "name": "ompenaclid", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Inspirna, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2018-06-05", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 17, "location_summary": "Prescott Valley, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03597581" }, { "nct_id": "NCT00079833", "title": "Esomeprazole In Patients With Gastric Acid Hypersecretory States Including Idiopathic Hypersecretion and Zollinger-Ellison Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Zollinger-Ellison Syndrome" ], "interventions": [ { "name": "Esomeprazole magnesium (Nexium)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2003-11", "completion_date": "2005-07", "has_results": false, "last_update_posted_date": "2010-11-19", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 5, "location_summary": "Los Angeles, California • Gainesville, Florida • Columbus, Ohio + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "King of Prussia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079833" }, { "nct_id": "NCT04408599", "title": "A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors", "Ovarian Cancer", "Gastric Cancer", "Colo-rectal Cancer" ], "interventions": [ { "name": "NC410", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-06-10", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-10-29T03:10:15.685Z", "location_count": 5, "location_summary": "Bethesda, Maryland • Hackensack, New Jersey • New York, New York + 2 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04408599" } ] }